Product Comparison


  Glaxo Smith Kline 58160082311 Glaxo Smith Kline 58160081912
McKesson # 1081079 1080947
Description Shingrix® Shingles Vaccine Indicated for People 50 Years of Age and Older Zoster Vaccine Recombinant, Adjuvanted 50 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL Shingrix® Shingles Vaccine Indicated for People 50 Years of Age and Older Zoster Vaccine Recombinant, Adjuvanted 50 mcg / 0.5 mL Injection Single-Dose Vial 0.5 mL
Manufacturer # 5816008231158160081912
Brand Shingrix®Shingrix®
Manufacturer Glaxo Smith KlineGlaxo Smith Kline
Invoice SHINGRIX VACC, SDV 50MCG/0.5ML0.5ML (10/BX)SHINGRIX VACC, SDV 50MCG/0.5ML0.5ML
    Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 3739620
NDC Number 5816008231158160-0819-12
Application Shingles VaccineShingles Vaccine
Container Type Single-Dose VialSingle-Dose Vial
Country of Origin UnknownUnknown
Dosage Form InjectionInjection
Generic Drug Code 4398943989
Generic Drug Name Zoster Vaccine Recombinant, AdjuvantedZoster Vaccine Recombinant, Adjuvanted
Product Dating McKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires RefrigerationRequires Refrigeration
Strength 50 mcg / 0.5 mL50 mcg / 0.5 mL
Type IntramuscularIntramuscular
UNSPSC Code 5120165051201650
User Indicated for People 50 Years of Age and OlderIndicated for People 50 Years of Age and Older
Volume 0.5 mL0.5 mL
Features and Benefits
  • SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older
  • SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox)
  • SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy
  • SHINGRIX is supplied as 2 components: A single-dose vial of lyophilized gE antigen component (brown cap) and a single-dose vial of adjuvant suspension component (blue-green cap) (packaged without syringes or needles)
  • A single dose after reconstitution is 0.5 mL
  • Administer 2 doses (0.5 mL each) at 0 and 2 to 6 months
  • 10 Doses
  • SHINGRIX is a vaccine indicated for prevention of herpes zoster (shingles) in adults aged 50 years and older
  • SHINGRIX is not indicated for prevention of primary varicella infection (chickenpox)
  • SHINGRIX is supplied as 2 components: A single-dose vial of lyophilized gE antigen component (brown cap) and a single-dose vial of adjuvant suspension component (blue-green cap) (packaged without syringes or needles)
  • A single dose after reconstitution is 0.5 mL
  • Administer 2 doses (0.5 mL each) at 0 and 2 to 6 months
  • 1 Dose